In 2006 JAMA published a study of industry initiated RCTs (in Denmark) where researchers from the Nordic Cochrane Centre and Oxford Centre for Statistics in Medicine found that in half, the sponsor owned the data, needed to approve the manuscript or both (but that this was not mentioned in any of the papers). In a large proportion of the trials, the sponsor had access to accumulating data (and therefore would have have the ability to terminate the trial at a point of their choosing) but this was again rarely mentioned. Similarly, in many cases the sponsor had the right to end the trial at any time, and this was never mentioned. The authors called for improved transparency, with publicly registered protocols, and independent data monitoring committees. Subsequently, the Danish pharmaceutical industry association LIF wrote to the Danish Committees on Scientific Dishonesty to accuse the authors of scientific misconduct. All charges were eventually dismissed but the process took over a year.Lif also wrote to the authors' employers, to the Danish Medical Association, the Ministry of Health and the journal of the Danish Medical Association.